Evidence map›Paper›PMID 26751958›Full record

ArticlePloS one2016

Curiouser and Curiouser: The Macrocyclic Lactone, Abamectin, Is also a Potent Inhibitor of Pyrantel/Tribendimidine Nicotinic Acetylcholine Receptors of Gastro-Intestinal Worms.

Melanie Abongwa, Samuel K Buxton, Alan P Robertson, Richard J Martin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Functional genomics inProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Melanie AbongwaDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America.
Samuel K BuxtonDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America.
Alan P RobertsonDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America.
Richard J MartinDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America.
Iowa State University · US

Funding

RESISTANCE &MODULATION OF LEVAMISOLE RECEPTOR CHANNELSR01AI047194 · NIAID · IOWA STATE UNIVERSITY · PI MARTIN, RICHARD JOHN · 2001 to 2021
$5.8M
Cholinergic receptors on the nematode pharynx: an unexploited drug targetR21AI092185 · NIAID · IOWA STATE UNIVERSITY · PI ROBERTSON, ALAN P · 2011 to 2012
$415k
NIAID NIH HHS R01 AI047194NIAID NIH HHS R01AI047194NIAID NIH HHS R21 AI092185NIAID NIH HHS R21AI092185-01A1
6 · The paper itself

Abstract

Nematode parasites may be controlled with drugs, but their regular application has given rise to concerns about the development of resistance. Drug combinations may be more effective than single drugs and delay the onset of resistance. A combination of the nicotinic antagonist, derquantel, and the macrocyclic lactone, abamectin, has been found to have synergistic anthelmintic effects against gastro-intestinal nematode parasites. We have observed in previous contraction and electrophysiological experiments that derquantel is a potent selective antagonist of nematode parasite muscle nicotinic receptors; and that abamectin is an inhibitor of the same nicotinic receptors. To explore these inhibitory effects further, we expressed muscle nicotinic receptors of the nodular worm, Oesophagostomum dentatum (Ode-UNC-29:Ode-UNC-63:Ode-UNC-38), in Xenopus oocytes under voltage-clamp and tested effects of abamectin on pyrantel and acetylcholine responses. The receptors were antagonized by 0.03 μM abamectin in a non-competitive manner (reduced Rmax, no change in EC50). This antagonism increased when abamectin was increased to 0.1 μM. However, when we increased the concentration of abamectin further to 0.3 μM, 1 μM or 10 μM, we found that the antagonism decreased and was less than with 0.1 μM abamectin. The bi-phasic effects of abamectin suggest that abamectin acts at two allosteric sites: one high affinity negative allosteric (NAM) site causing antagonism, and another lower affinity positive allosteric (PAM) site causing a reduction in antagonism. We also tested the effects of 0.1 μM derquantel alone and in combination with 0.3 μM abamectin. We found that derquantel on these receptors, like abamectin, acted as a non-competitive antagonist, and that the combination of derquantel and abamectin produced greater inhibition. These observations confirm the antagonistic effects of abamectin on nematode nicotinic receptors in addition to GluCl effects, and illustrate more complex effects of macrocyclic lactones that may be exploited in combinations with other anthelmintics.

Indexed as

AcetylcholineAllosteric SiteAnimalsAnthelminticsCloning, MolecularDose-Response Relationship, DrugGastrointestinal TractGene Expression RegulationHaemonchusHelminthiasisIndolesIntestinal Diseases, ParasiticIvermectinNematodaNicotinic AntagonistsOocytesabamectinAcetylcholineAnthelminticsderquantelIndolesIvermectinNicotinic AntagonistsOxepinsPhenylenediaminesPyrantelReceptors, Nicotinictribendimidine

Identifiers

PMID26751958
PMCPMC4709073
OpenAlexW2239168304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.